Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

49.38 +0.34 (+0.68%)

Streaming Delayed Price Updated: 3:07 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

83 84 Next >

Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch. ↗

July 25, 2025

Via The Motley Fool

2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky

July 25, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Topics Economy

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

July 24, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' ↗

July 24, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings.

Via Benzinga

Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking ↗

July 18, 2025

Via Stocktwits

Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours ↗

July 17, 2025

Via Stocktwits

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 23, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks

July 23, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Peering Into Bristol-Myers Squibb's Recent Short Interest ↗

July 23, 2025

Via Benzinga

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings ↗

July 22, 2025

Via Benzinga

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks ↗

July 22, 2025

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Via Benzinga

3 Value Stocks We’re Skeptical Of

July 22, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

July 21, 2025

Via Benzinga

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July 21, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial ↗

July 18, 2025

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients.

Via Benzinga

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

July 18, 2025

From Bristol Myers Squibb

Via Business Wire

Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks

July 17, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off ↗

July 17, 2025

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - An Undervalued Stock with Strong Fundamentals ↗

July 17, 2025

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is an undervalued pharmaceutical stock with strong profitability, a high dividend yield, and attractive valuation metrics, making it a candidate for value investors.

Via Chartmill

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

July 17, 2025

From Bristol Myers Squibb

Via Business Wire

Don’t Miss These 4 Stocks With Explosive Dividend Yields ↗

July 15, 2025

Via MarketBeat

Topics Stocks

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

1 Safe-and-Steady Stock with Exciting Potential and 2 to Brush Off

July 14, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today

July 11, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other...

Via StockStory

Topics ETFs Intellectual Property Stocks

Top S&P500 movers in Friday's session ↗

July 11, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

July 11, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? ↗

July 11, 2025

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with...

Via Benzinga

What's going on in today's session: S&P500 gap up and gap down stocks ↗

July 11, 2025

Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

83 84 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.